Selective, Nontoxic CB2 Cannabinoid o‑Quinone with in Vivo Activity against Triple-Negative Breast Cancer
journal contributionposted on 12.03.2015 by Paula Morales, Sandra Blasco-Benito, Clara Andradas, María Gómez-Cañas, Juana María Flores, Pilar Goya, Javier Fernández-Ruiz, Cristina Sánchez, Nadine Jagerovic
Any type of content formally published in an academic journal, usually following a peer-review process.
Triple-negative breast cancer (TNBC) represents a subtype of breast cancer characterized by high aggressiveness. There is no current targeted therapy for these patients whose prognosis, as a group, is very poor. Here, we report the synthesis and evaluation of a potent antitumor agent in vivo for this type of breast cancer designed as a combination of quinone/cannabinoid pharmacophores. This new compound (10) has been selected from a series of chromenopyrazolediones with full selectivity for the nonpsychotropic CB2 cannabinoid receptor and with efficacy in inducing death of human TNBC cell lines. The dual concept quinone/cannabinoid was supported by the fact that compound 10 exerts antitumor effect by inducing cell apoptosis through activation of CB2 receptors and through oxidative stress. Notably, it did not show either cytotoxicity on noncancerous human mammary epithelial cells nor toxic effects in vivo, suggesting that it may be a new therapeutic tool for the management of TNBC.